Arbutus Biopharma announces abstracts highlighting imdusiran data

Arbutus Biopharma announced that clinical data with imdusiran, an RNAi therapeutic, will be highlighted in four poster presentations at the American Association for the Study of Liver Diseases – The Liver Meeting 2024, scheduled from November 15-19, 2024 in San Diego, CA. This includes two late-breaking posters with imdusiran data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials. Presentation Title: Soluble Immune Biomarker Profiling of Chronic Hepatitis B Subjects Treated with Imdusiran in Combination with Pegylated Interferon Alfa Reveals Phases of Immune Activation: Key Findings: Imdusiran treatment in combination with IFN was associated with distinct phases of soluble immune biomarker signatures. Immune biomarkers associated with Th1 immune activation and regulation of inflammation were observed in subjects during imdusiran lead-in, coinciding with the establishment of a plateau in HBsAg reduction. Secondary transient elevations of these immune biomarkers were observed to occur during IFN treatment and were followed by appearance of Th2 immune biomarker signatures that were associated with HBsAg seroconversion. Presentation Title: HBV Target Site for the RNA Interference Therapeutic Imdusiran is Highly Conserved in Chronic Hepatitis B Subjects: Key Findings: The imdusiran target site is highly conserved in baseline samples from cHBV subjects enrolled in imdusiran clinical studies assessed to date. In vitro testing in an HBV cell-based model confirmed retention of imdusiran activity against tested variants, suggesting that these single nucleotide polymorphisms have no apparent influence on HBsAg declines in subjects treated with imdusiran. Imdusiran has demonstrated clinical activity against HBV genotypes A-E.